Breaking News From Pharma & Bio Ingredients
Genitope Initiates Clinical Trial for Chronic Lymphocytic Leukemia Treatment
Posted on 2006-02-27 08:40:00
Genitope Corporation today announced the initiation of a clinical trial to evaluate the use of MyVax personalized immunotherapy to treat Chronic Lymphocytic Leukemia (CLL), a type of cancer affecting the blood and bone marrow. MyVax personalized immunotherapy is based on the unique genetic makeup of a patient's own tumor, and is designed to activate the patient's immune system to fight cancer.
"Active immunotherapy, sometimes called a cancer vaccine, has shown considerable promise in treating non-Hodgkin's lymphoma," said Dan W. Denney, Jr., Ph.D., chief executive officer of Genitope. "The initiation of this trial marks a key milestone in our efforts to expand the clinical development of MyVax® personalized immunotherapy beyond non-Hodgkin's lymphoma in the hope of finding an effective treatment for CLL."
Nine leading North American cancer centers will begin registering approximately 70 patients in a Phase I/II clinical trial to investigate MyVax® personalized immunotherapy for treating CLL. Men and women 18 years of age or older who have been diagnosed with CLL Rai stage 0, I and II, and who are untreated may be eligible for the study. Eligible patients will receive a series of 16 injections of his or her custom-made immunotherapy over a 52-week period.
Subscribe via RSS
